Condition: Solid Tumors, Adult · Sponsor: Grit Biotechnology
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes： 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).
This description comes directly from the study's public registry record.
Haifeng Qin, PhD · +86 13601365243 · hifo@263.net
Yongsheng Wang, PhD · wangy756@163.com
Always discuss trial participation with your own doctor first.
| The fifth medical center of the General Hospital of the Chinese people's Liberation Army | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Center | Chongqing, Chongqing Municipality, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| West China School of Medicine/West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05430373